Immunological evaluation of a ribosomal vaccine in patients with recurrent bronchitis

To determine the effect of treatment with a ribosomal vaccine [Ribomunyl] on the different immune functions, 28 patients with recurrent bronchitis were studied before and after vaccine administration for 3 months. 19 placebo were included in this double blind study. Clinical evaluation of cases, delayed hypersensitivity skin testing, E-rosette test, leucocyte migration inhibition test and serum Ig levels were done before and at the end of treatment in patients and placebo. Clinical improvement in patients receiving the vaccine was linked to statistically significant increases in E-rosette%, migration inhibition and IgM, G and A levels together with normalization of IgE levels which were initially raised in 4 patients. The results indicated that the vaccine has potent immunotherapeutic effects and confirm its efficiency and the interest of its use in patients with recurrent bronchitis

efficacy of cefuroxime in the treatment of bacterial meningitis in infants and children

Fortyeight cases of proven bacterial meningitis due to one of six causative organisms were treated with cefuroxime. Cefuroxime was clinically and bacteriologically effective in 40 cases. Failure of response was due to one of several factors infection with resistant organism e.g. staph. aureus resistant to the drug, bad general condition, fulminating forms of the disease and rapid death with no sufficient duration of therapy. Cefurozime, on the whole could be considered as the drug of choice for the treatment of meningitis due to Str. pneumoniae, N meningitidis, Staph. aureus, salmonella and H. influenzae